NEW YORK (GenomeWeb News) — Sysmex Inostics said today that it has inked a collaboration agreement with Bayer Healthcare to develop blood-based companion diagnostics for targeted anti-cancer therapies being developed by Bayer.

Under the agreement, Sysmex Inostics, a subsidiary of Japanese in vitro diagnostics firm Sysmex, will develop blood-based diagnostic tests using its BEAMing technology, an ultra-sensitive digital PCR approach that can detect cancer cell DNA directly from blood.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.